We report a case of a 42-year-old man who presented with progressive weakness and blindness over the course of several months and met criteria for seronegative neuromyelitis optica. This presentation was in the setting of immunosuppression following cardiac transplant. No infectious causes were found within the neuroaxis, and he ultimately died with complete blindness, quadriplegia, and respiratory failure attributed to panmyelitis and brain stem inflammation despite aggressive therapies. N euromyelitis optica (NMO) is a rare infl ammatory demyelinating disease that aff ects the optic nerves, brainstem, and spinal cord, resulting in varying degrees of blindness and paralysis. Once considered a subclass of multiple sclerosis, it has emerged as its own entity with the discovery of an associated autoantibody, aquaporin-4, present in a majority of patients (1). Th e antibody is absent in a subset of patients (2) where other antibodies are thought to play a role. Th e anti-MOG antibody may be linked to NMO, but was commercially unavailable for testing at the time of our patient's illness (3). Current treatments are noncurative and include trials of immunosuppressants and immunomodulators (4). We report a case of a patient who, despite being on immunosuppression after a heart transplant, presented with seronegative NMO.
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CASE DESCRIPTION
A 42-year-old black man with prior orthotopic heart transplant for nonischemic cardiomyopathy and end-stage renal disease from immunosuppressant therapy presented with severe burning pain in his legs bilaterally. Th e symptoms were fi rst noticed about 2 years posttransplant and had gradually worsened over 2 months. Initial examination showed hyperesthesia from L2 on the right and L1 on the left. Th e patient refused a lumbar puncture at that time, citing improved pain with gabapentin, and wished to go home with outpatient follow-up. Th e patient was fully ambulatory at the time of discharge.
He gradually developed weakness in his legs and noticed some blurry vision. Examination on his second admission, 5 weeks later, showed weakness in both legs, distal (3 of 5) greater than proximal (4-of 5). Deep ten don refl exes were hyperrefl exive at the knees with clonus at the ankles. Strength in the upper extremities was mildly decreased (4 of 5). He had a bilateral T8 sensory level, but was not incontinent. Visual acuity was decreased in his right eye with large sluggishly reactive pupils.
Repeat magnetic resonance imaging (MRI) of his spine showed increased T2 hyperintensity throughout the central gray matter with diff use cord signal change and minimal cord expansion ( Figure 1 ). MRI of the orbits showed fl uid attenuation inversion recovery (FLAIR) hyperintensity of the bilateral anterior optic pathway, and MRI of the brain showed brainstem FLAIR signal elevation with subtle contrast enhancement. Th e cerebral hemispheres showed only some encephalomalacia from known previous asymptomatic strokes that occurred at the time of his cardiac transplant with no signs of demyelination. Comprehensive rheumatologic and infectious workups were unremarkable (Table 1) . Aquaporin-4 IgG was negative. Cerebrospinal fl uid analysis disclosed an elevated protein (62 mg/dL) with a normal cell count and diff erential.
Within a week of hospitalization, the patient was quadriplegic, ventilator dependent, incontinent, and completely blind. He was treated with broad-spectrum antibiotics, antifungals, and antivirals. He was treated for presumed NMO aggressively with highdose methylprednisolone and plasmapheresis (fi ve cycles) followed by intravenous immunoglobulin (2.3 g/kg), with no response. His hospital course was complicated by healthcare-associated pneumonia and later a gastrointestinal bleed secondary to cytomegalovirus colitis. Th e patient remained cognitively intact and was transitioned to comfort care per his wishes and died shortly thereafter.
Th e patient and his father granted an autopsy. His fi xed brain weighed 1550 g with signifi cant gyral fl attening and sulcal narrowing consistent with edema. Th e cranial nerves appeared grossly intact, except the right optic nerve appeared smaller than the left. On coronal sectioning, no gross abnormalities were seen throughout the cerebral hemispheres. Sectioning through the cerebellum found a 1.1 × 0.8 cm wedged-shaped area of volume loss with brown discoloration at the left medial posterior aspect. No gross abnormalities were identifi ed in the pons, midbrain, medulla, or spinal cord.
Microscopically (Figure 2) , there was a remote incomplete infarct with marked neuron and volume loss in the left cerebellar hemisphere corresponding to the lesion seen grossly. Th e most signifi cant lesions seen microscopically were located within the midbrain, pontomedullary junction, multiple levels of the spinal cord, and the optic nerves. Th ese areas all showed similar histologic fi ndings characterized by extensive areas of pallor and vacuolization with an infl ammatory infi ltrate composed predominantly of macrophages. Extensive myelin loss was identifi ed throughout these areas and was highlighted with a Luxol fast blue stain. Additionally, focal axonal loss was also confi rmed by a neurofi lament immunohistochemical stain. Th e characteristic features of cytomegalovirus infection were not identifi ed.
DISCUSSION
Devic and Gault fi rst described patients with NMO in 1894 (5). It is an infl ammatory demyelinating disease that initially spares the brain but attacks the optic nerves and spinal cord with varying severity. Th e condition aff ects women nine times more frequently than men, with the median age in the fourth decade. Th e prognosis is poor, as no current therapies are curative.
Originally categorized as a subclass of multiple sclerosis, NMO was later established as a separate disease with the discovery of a specifi c biomarker, aquaporin-4 IgG (1). Aquaporin-4 is the major water channel in the brain, optic nerve, and spinal cord and thus a major contributor to water homeostasis (6). Th e sensitivity of this antibody has been reported to be 73% and the specifi city, 91% (1, 7). A 2012 retrospective study reported that the presence or absence of the NMO antibody did not alter the overall mortality rate, age of presentation, or relapse rate. Th ose with seronegative NMO were more likely to have a monophasic course, bilateral eye involvement, and concurrent optic neuritis and myelitis (7), similar to our case.
In 2006, Wingerchuk and colleagues revised the diagnostic criteria for NMO to include the discovered autoantibody (8). Th e patient must present with optic neuritis and acute myelitis. In addition, two of three of these criteria must be met: 1) MRI shows a spinal cord lesion that spans >3 vertebral segments; 2) patient does not meet the criteria for multiple sclerosis based on MRI; and 3) patient tests positive for aquaporin-4 IgG.
Treatment is limited and usually focused on immunosuppression. Th e typical algorithm is to start the patient having active If the patient fails to respond or if the symptoms are severe, administration of 2 g/kg of intravenous immunoglobulin, sometimes preceded by plasma exchange, may be considered. Some reports suggest that NMO is more responsive to plasma exchange than to either steroids or intravenous immunoglobulin (4). To reduce relapses, immunosuppression is used, with rituximab, azathioprine, cyclophosphamide, and mycophenolate the agents of choice (4 no eff ect on the disease process and may even be harmful (4). Our patient failed to respond to any of these therapies. Furthermore, he had already been immunosuppressed with tacrolimus, mycophenolate mofetil, and prednisone. Th us, how he developed this condition in the setting of immunosuppression was puzzling.
